Skip to content

    Recently Viewed

      Listening...

      Home / Latest news /
      Johnson & Johnson executive Jennifer Taubert named to Fortune’s 2022 Most Powerful Women list
      johnson-johnson-executive-jennifer-taubert-named-to-fortunes-2022-most-powerful-women-in-business-1022.jpeg

      Johnson & Johnson executive Jennifer Taubert named to Fortune’s 2022 Most Powerful Women list

      The company leader has been named to the prestigious list—which honors 50 women at the top of their industries—for the seventh year in a row.

      Share Article
      share to

      As a testament to her leadership and influence, Jennifer Taubert, Executive Vice President and Worldwide Chairman, Pharmaceuticals at Johnson & Johnson, has been named to Fortune’s 2022 list of the Most Powerful Women for the seventh consecutive year.

      The annual ranking is based on five criteria: the size and importance of a leader’s business in the global economy, the health and direction of the business, the arc of her career, her social and cultural influence and how she uses her position to help shape her company and the world beyond.

      Taubert checks all those boxes.

      Dedication to Putting Patients First

      As head of the Janssen Pharmaceutical Companies of Johnson & Johnson, Taubert is charged with guiding Janssen’s global efforts to develop and deliver innovative medicines to transform the lives of millions around the world.

      In the past year alone, that strategy has led to a number of “firsts” for novel therapies, including the launch of Janssen’s first cell therapy, for multiple myeloma; a treatment for non-small cell lung cancer for patients with a specific genetic mutation; and a twice-yearly injectable for schizophrenia in adults.

      In 2021, Janssen invested $11.9 billion in research and development, a 24% increase over 2020, demonstrating Taubert’s ongoing commitment to tackling some of the world’s most devastating diseases today and in the future. Indeed, as the latest U.S. Transparency Report shows, Janssen is among the top investors in R&D across all industries worldwide.

      “Jennifer has dedicated her career to making a global impact in healthcare. At Johnson & Johnson that means putting patients and all those we serve at the center of everything we do,” says Joaquin Duato, Chief Executive Officer, Johnson & Johnson. “She is an inspirational leader and truly deserving of this recognition once again.”

      Commitment to the Company’s Values

      Taubert has leveraged her influence to advance a culture of diversity, equity and inclusion at Johnson & Johnson. As Executive Committee sponsor of the company’s Alliance for Diverse Abilities Employee Resource Group, she’s championed a number of initiatives that support employees living with diverse physical, neurological and mental health abilities. And that’s not all.

      Recognizing the COVID-19 pandemic’s continuing toll on frontline workers, she also drives the company’s support for nurses and other critical healthcare providers; most notably, Johnson & Johnson’s support for the Dr. Lorna Breen Health Care Provider Protection Act, the first national legislation to improve the mental health and well-being of U.S. health workers.

      Johnson & Johnson applauds Taubert on this repeat honor, which reflects her unwavering commitment to helping change the trajectory of human health.

      Inspiring the next generation of women in STEM

      Johnson & Johnson’s WiSTEM 2D program is dedicated to furthering the goals of girls and women in science, math, tech, medicine, engineering, and design.

      More from Johnson & Johnson

      Innovation
      Headshots of three Johnson and Johnson female scientists

      Meet 3 leaders who are breaking new ground for women in healthcare

      For International Women’s Day, celebrate the achievements of these amazing female scientists and researchers at Johnson & Johnson.
      Innovation
      Close-up of a woman with low vision receiving an eye exam exam with a doctor shining light into her left eye

      What is low vision?

      Low vision isn’t the same as blindness, but navigating daily life with it is still challenging. For Low Vision Awareness Month, learn the facts—plus, the promising treatment innovations that are in the works.
      Innovation
      A female scientist conducting research in a laboratory, focusing on orphan drugs for rare diseases

      What is an orphan drug?

      The need for these rare disease therapies is strong, and access to them can be lifesaving. Here’s how Johnson & Johnson is innovating to help give patients options.
      You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.